Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma

CONCLUSIONS: The pretreatment NLR value may be a useful predictor of response to Atezo/Bev therapy for HCC.PMID:34677270 | PMC:PMC8534657 | DOI:10.3390/curroncol28050352
Source: Current Oncology - Category: Cancer & Oncology Authors: Source Type: research